A good win for the company. Three more years to try and get patients on other formulations and/or development something else. I've been out for a while I don't have high confidence that they'll be as successful at developing/licensing other products. If the oral product were better tolerated I would have had more confidence in getting a prostacylin to work in other indications. PAH has also become quite competitive.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.